Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment.
Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment.
复制标题
DOI：
10.1007/s12471-017-0959-2
复制
发表时间：
2017-04
期刊：
影响因子：
--
通讯作者：
Jukema JW
中科院分区：
文献类型：
--
作者：
Bergheanu SC;Bodde MC;Jukema JW
近年来，动脉粥样硬化领域出现了大量新的研究成果。更好地了解不同脂蛋白颗粒在动脉粥样硬化斑块形成中的作用现在是可能的。最近的心血管临床试验也揭示了针对动脉粥样硬化主要途径及其心血管并发症的新型化合物的有效性和安全性。在这篇综述中，我们首先提供了一个背景，包括目前对动脉粥样硬化疾病的病理生理和治疗的理解，然后是我们对几种针对动脉粥样硬化的新型药物的未来展望。本次更新的重点是低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、甘油三酯（TG）和脂蛋白(a) （Lp(a)）的病理生理学和医学干预。
Recent years have brought a significant amount of new results in the field of atherosclerosis. A better understanding of the role of different lipoprotein particles in the formation of atherosclerotic plaques is now possible. Recent cardiovascular clinical trials have also shed more light upon the efficacy and safety of novel compounds targeting the main pathways of atherosclerosis and its cardiovascular complications. In this review, we first provide a background consisting of the current understanding of the pathophysiology and treatment of atherosclerotic disease, followed by our future perspectives on several novel classes of drugs that target atherosclerosis. The focus of this update is on the pathophysiology and medical interventions of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and lipoprotein(a) (Lp(a)).